Advertisement

The Current Status for Metformin Use in Reproductive Medicine

  • Richard S. Legro
Chapter

Abstract

Metformin has been used extensively in multiple reproductive settings to ameliorate hyperandrogenism and chronic anovulation, to treat infertility, to prevent miscarriage and to prevent later pregnancy complications as well. Metformin does result in modest improvements in the PCOS phenotype with reductions in circulating insulin and testosterone levels, weight loss, and improved menstrual/ovulatory frequency. It is relatively ineffective as a solo agent to treat infertility, and further has a relative anti-fecundity compared to clomiphene alone. Clomiphene remains the first choice for infertility therapy and the gold standard for women with PCOS. Metformin may be useful in preventing OHSS when used in conjunction with gonadotropins. The use of metformin to prevent pregnancy loss or to prevent pregnancy complications is still experimental and better trials are needed to guide therapy.

Keywords

Metformin PCOS Diabetes Ovulation induction Clomiphene citrate 

References

  1. 1.
    Fujioka K, Brazg RL, Raz I et al (2005) Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 7(1):28-39CrossRefPubMedGoogle Scholar
  2. 2.
    Levri KM, Slaymaker E, Last A et al (2005) Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 3(5):457-461CrossRefPubMedGoogle Scholar
  3. 3.
    Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403CrossRefPubMedGoogle Scholar
  4. 4.
    Legro RS, Barnhart HX, Schlaff WD et al (2007) Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356(6):551-566CrossRefPubMedGoogle Scholar
  5. 5.
    Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84(1):165-169CrossRefPubMedGoogle Scholar
  6. 6.
    Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN (2005) Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 90(1):66-71CrossRefPubMedGoogle Scholar
  7. 7.
    Moghetti P, Castello R, Negri C et al (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85(1):139-146CrossRefPubMedGoogle Scholar
  8. 8.
    Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R (1998) Effects of metformin on spontaneous and clomiphene-induced ovula­tion in the polycystic ovary syndrome. N Engl J Med 338(26):1876-1880CrossRefPubMedGoogle Scholar
  9. 9.
    Myers ER, Silva SG, Hafley G, Kunselman AR, Nestler JE, Legro RS (2005) Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial. Contemp Clin Trials 26(3):271-280CrossRefPubMedGoogle Scholar
  10. 10.
    Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F (2006) Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332(7556):1485CrossRefPubMedGoogle Scholar
  11. 11.
    Palomba S, Orio F Jr, Falbo A et al (2005) Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90(7):4068-4074CrossRefPubMedGoogle Scholar
  12. 12.
    Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F (2007) Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. J Clin Endocrinol Metab 92(9):3498-3503CrossRefPubMedGoogle Scholar
  13. 13.
    Moll E, van der Veen F, van Wely M (2007) The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 13(6):527-537CrossRefPubMedGoogle Scholar
  14. 14.
    Tang T, Glanville J, Orsi N, Barth JH, Balen AH (2006) The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 21(6):1416-1425CrossRefPubMedGoogle Scholar
  15. 15.
    Asch RH, Greenblatt RB (1976) Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. J Reprod Med 17(3):175-180PubMedGoogle Scholar
  16. 16.
    Casper RF, Mitwally MF (2006) Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91(3):760-771CrossRefPubMedGoogle Scholar
  17. 17.
    Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87(2):524-529CrossRefPubMedGoogle Scholar
  18. 18.
    Palomba S, Orio F Jr, Nardo LG et al (2004) Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 89(10):4801-4809CrossRefPubMedGoogle Scholar
  19. 19.
    Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS (2006) A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 12(6):673-683CrossRefPubMedGoogle Scholar
  20. 20.
    Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM (2004) Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 19(8):1734-1740CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyPenn State College of Medicine, M.S. Hershey Medical CenterHersheyUSA

Personalised recommendations